T he 2004 Nobel Prize in chemistry has been awarded to three biochemists. As stated in an announcement from the Royal Swedish Academy of Sciences on 6 November 2004, Aaron Ciechanover, Avram Hershko (both at the Israel Institute of Technology) and Irwin Rose (University of California at Irvine) were recognized for "the discovery of ubiquitin-mediated protein degradation."
transcription, DNA repair, inflammation and immune responses, just to name a few. In this regard, it is essential that protein substrates be ubiquitinated in a highly specific and regulated manner. This specificity is achieved by having in the cell a single ATP-consuming E1 that transfers ubiquitin to several E2s, which then cooperate with many E3s that specifically recognize their substrates. In this context, the complexity of the three-tier ubiquitination process makes sense.
The utility of ubiquitination does not end with protein degradation. For example, the attachment of ubiquitin to many receptors on the cell surface regulates their transport through the endocytic pathway. Ubiquitination also seems to be involved in the budding of viral particles from the cell surface. Finally, it has long been known that histone proteins are ubiquitinated, and recent research has begun to reveal that such modifications have a role in both transcription activation and gene silencing. Ubiquitination is thus an integral part of the 'histone code. ' Several proteins are closely related to ubiquitin, and their functional mechanisms involve conjugation of these proteins to their targets. These include bacterial proteins ThiS and MoaD, which are components of the thiamin and molybdenum cofactor biosynthesis pathways, respectively, as well as eukaryotic proteins such as NEDD8, SUMO and some of the autophagins, which seem to be involved in ubiquitination, nuclear transport/transcription repression and autophagy, respectively. Despite the diverse origins and functions of these proteins, they have conjugation systems similar to that for ubiquitin. Thus, the biochemical pathway developed for ubiquitin has been adapted for different biological processes.
The importance of the proteasome in regulating various cellular processes also makes it an attractive therapeutic target, especially as a potential cancer treatment. In fact, proteasome inhibitors are a new class of drugs currently in development, and one of these drugs, bortezomib, has recently been approved in the United States to treat multiple myeloma. Other potential areas for proteasome inhibitors as treatment include anti-angiogenesis and diseases related to the immune system, such as chronic inflammatory conditions, multiple sclerosis and rheumatoid arthritis. In recognition of the broad implications of the regulated protein degradation mediated by the ubiquitin system, Ciechanover and Hershko were also the co-recipients of the Albert Lasker Award for basic medical research in 2000 (shared with Alexander Varshavsky).
Looking back, it is interesting to see how a relatively simple set of biochemical experiments almost three decades ago led to the emergence of an important field that impacts many different areas of biol- 
